ARCHIVES

House Committee Aims To Cut Markup On Office-Administered Cancer Drugs.

This article is from The Cancer Letter archive.

Vol. 27 No. 42 | November 16, 2001

Download PDF Visit The Full Archive

Related Articles

Talking Back: FDA Faces Challenges Over Avastin & Prostate Cancer Prevention

January 21, 2011

Surgeons Responsible For Improving Their Role, CCIRC Says

July 8, 1977

Group Chairmen Reject DCT’s Agenda For Clinical Trials Review, demand Right To Select Speakers

June 30, 1978

Final Issue Of 1992

December 11, 1992

NCI Starts “Exceptional Responders” Study

September 26, 2014

Kulig Will Oversee Outcomes Research at NCCN

September 30, 2011